Reuters logo
3 months ago
BRIEF-Array Biopharma announces positive top-line results from part 2 of the phase 3 columbus study of binimetinib and encorafenib
May 9, 2017 / 8:49 PM / 3 months ago

BRIEF-Array Biopharma announces positive top-line results from part 2 of the phase 3 columbus study of binimetinib and encorafenib

May 9 (Reuters) - Array Biopharma Inc

* Array Biopharma announces positive top-line results from part 2 of the phase 3 Columbus study of binimetinib and encorafenib for braf-mutant melanoma

* Array Biopharma Inc - new drug application filing on track for June or July 2017

* Array - median PFS for patients on combination of binimetinib (45mg) plus encorafenib (300mg) 12.9 months versus 9.2 months for patients on encorafenib (300mg)

* Array Biopharma Inc- COMBO300 generally well-tolerated, reported dose intensity, adverse events were consistent with COMBO450 results in Columbus part 1 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below